CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
✉ Email this page to a colleague
All Clinical Trials for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02798757 ↗ | Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy | Completed | University of Ioannina | Phase 4 | 2016-06-01 | This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
Condition Name
Clinical Trial Locations for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
Clinical Trial Progress for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate
Sponsor Name
| Sponsor Name for amino acids; magnesium acetate; potassium acetate; sodium chloride; sodium phosphate, dibasic, heptahydrate | |
| Sponsor | Trials |
| University of Ioannina | 1 |
| Alphacait, LLC | 1 |
| Haining Health-Coming Biotech Co., Ltd. | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
